=====================
SPEX (Spherix Incorporated)
Float: 1.98M
Alert Price: $2.97
CEO Interview
Chart Analysis
Website | Recent News
========================
Add SPEX to the top of your watchlist. See why this low-float alert could be the Nasdaq's top gainer
Members,
Earlier today we told you that we had a fresh low-float, Nasdaq listed opportunity on our radar.
Now we ask that you please put your immediate attention on SPEX (Spherix Incorporated).
This technology development company committed to the fostering of innovative ideas is shaping up to be one of our most exciting growth plays of 2019!
SPEX is Developing Game-Changing Drugs for the Treatment of Pancreatic Cancer & Leaukemia
Just a few weeks ago, on May 16th, SPEX announced the terms of an Asset Purchase Agreement with CBM BioPharma.
SPEX “purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board.”
Here’s a little about the company’s new investment:
CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.
CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.
The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and pancreatic cancer.
Two specific proprietary drugs that are currently being researched are:
KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia”
DHA-dFdC (Pancreatic Cancer Drug)”
KPC34 “is a next generation treatment” that “has also been shown to be more effective in AML relapse cases” and “has served to double the mean survival time of patients versus the current standard of care treatments.”
Click here of a must see video on KPC34
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
DHA-dFdC, the company’s second drug, “has shown positive results in preclinical studies, inhibiting pancreatic tumor growth” and “also overcomes tumor cell resistance to current chemotherapeutic drugs.”
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
There is a huge need for innovation and improvement to address these serious diseases.
Plus, recently the company announced that their Preclinical Pancreatic Cancer Treatment Study will be Moving Forward.
The global treatment costs for both these diseases are in the multi-billions and continue to grow.
Given SPEX’s prior successes, they could be best suited to help advance these key projects to market and provide help to those suffering.
SPEX also released the following info that is sure to grab the attention of the Street
The Company has total assets of $11,937,000.
The Company has liabilities of $982,000.
A snapshot of a data point for sure, but compelling, confidence inspiring statistics that reflect a risk-taker of a company with interests in a myriad of lucrative verticals which cashed in big on one of its earliest investments, dropping two million shares into the proforma when an early stage investment IPO'd and a hypothetical windfall became an actual one.
The asset/liability ratio alone should raise Spherix's street cred above other companies in any of its targeted industries where blue sky optimism and 'someday' dialogue too often suffice in lieu of real asset gains or profits.
But perhaps what is most compelling when considered in the context of this stirring asset/liability chasm is another singular number:
The Company has 2,010,074 shares of common stock outstanding.
Nearly $12 million in assets as of the last Q, just under a million in debt, and roughly 2 million shares in play. Post that snippet on your favorite stock message board and see what the natives say.
We'll let the reader do the math on their own as the share price changes daily, but it's more than a little interesting to consider Spherix's present and future simply going by the numbers.
Source: www.accesswire.com/5...ports-By-the-Numbers
About Spherix
Spherix Incorporated is a technology development company committed to the fostering of innovative ideas. Spherix Incorporated was formed in 1967 as a scientific research company.
Their activities generally include the acquisition and development of technology through internal or external research and development. In addition, they seek to acquire existing rights to intellectual property through the acquisition of already issued patents and pending patent applications, both in the United States and abroad. They may alone, or in conjunction with others, develop products and processes associated with technology development and monetizing related intellectual property.
Company Highlights:
Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
Company filed its Form-10Q for the period ended March 31, 2019, which showed total assets of $11,937,000.00 and liabilities of $982,000.00, with 2,010,074 shares of common stock outstanding.
In addition, the Company announced a restructuring of the terms of its proposed merger with CBM BioPharma, Inc. (CBM), a Delaware corporation. In lieu of the previously announced merger, the Company announced the terms of an Asset Purchase Agreement with CBM, whereby the Company purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board. The revised agreement is significantly less dilutive to Spherix shareholders, as Spherix is paying $8,000,000.00 to CBM in total compensation, as opposed to the previously announced $16,500,000.00, as more fully set forth in the Company's filings. The acquisition of CBM's assets is pending shareholder approval.
In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation. The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
Mr. Anthony Hayes, CEO of Spherix stated, "The revised negotiated terms with CBM BioPharma in the Asset Purchase Agreement will introduce valuable assets into the Spherix family. The new agreement will be less dilutive to Spherix shareholders. I am also pleased to note that CBM has received some early, favorable correspondence from the Patent Office about its University of Texas patent applications. We will provide additional information as it comes available, but it is certainly a positive development for CBM."
"Post-closing, Spherix shareholders will still own a majority interest in the Company. Further, Spherix's 20% ownership in CBM is an accretive benefit to Spherix shareholders and by having an ownership interest in CBM, Spherix will participate in any dividend distributions made by CBM in the future. This may include cash dividends that might result from the future sale of Spherix stock. We look forward to sharing additional information with our shareholders about the proposed asset purchase in the upcoming weeks through both investor outreach and our upcoming SEC filings."
Market Outlook:
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
The global pancreatic cancer treatment market size was valued at USD 1.7 billion in 2015. The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel the market growth.
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
The Global Leukemia Therapeutic Market is expected to exceed more than US$ 12.50 Billion by 2024 at a CAGR of 4% in the given forecast period.
There is a huge need for innovation and improvement to address these serious diseases.
Technical Analysis
Like all low-float alerts, SPEX has the potential to run-up big on volume.
The chart looks extremely attractive at the moment.
The price appears to have consolidated, and is now in the apex with an explosive move higher impending.
Its retrace appears complete, and looks to have developed strong support at these levels.
Bases on our very own chart analysis, we see the potential for a move of over +70%!
The Bottom-Line
SPEX looks like a winner in both the financial and technical sides.
This should be the only ticker on your radar tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings LLC to conduct a one-day investor relations advertising and marketing campaign for SPEX. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
SPEX (Spherix Incorporated)
Float: 1.98M
Alert Price: $2.97
CEO Interview
Chart Analysis
Website | Recent News
========================
Add SPEX to the top of your watchlist. See why this low-float alert could be the Nasdaq's top gainer
Members,
Earlier today we told you that we had a fresh low-float, Nasdaq listed opportunity on our radar.
Now we ask that you please put your immediate attention on SPEX (Spherix Incorporated).
This technology development company committed to the fostering of innovative ideas is shaping up to be one of our most exciting growth plays of 2019!
SPEX is Developing Game-Changing Drugs for the Treatment of Pancreatic Cancer & Leaukemia
Just a few weeks ago, on May 16th, SPEX announced the terms of an Asset Purchase Agreement with CBM BioPharma.
SPEX “purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board.”
Here’s a little about the company’s new investment:
CBM is a privately held pharmaceutical company with exclusive drug development rights from world-renowned partners including Wake Forest Innovations and the University of Texas at Austin.
CBM has a team of leading drug development scientists who will be joining Spherix as advisors to advance the technology.
The CBM platform focuses on the treatment of numerous cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and pancreatic cancer.
Two specific proprietary drugs that are currently being researched are:
KPC34 (Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia”
DHA-dFdC (Pancreatic Cancer Drug)”
KPC34 “is a next generation treatment” that “has also been shown to be more effective in AML relapse cases” and “has served to double the mean survival time of patients versus the current standard of care treatments.”
Click here of a must see video on KPC34
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
DHA-dFdC, the company’s second drug, “has shown positive results in preclinical studies, inhibiting pancreatic tumor growth” and “also overcomes tumor cell resistance to current chemotherapeutic drugs.”
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
There is a huge need for innovation and improvement to address these serious diseases.
Plus, recently the company announced that their Preclinical Pancreatic Cancer Treatment Study will be Moving Forward.
The global treatment costs for both these diseases are in the multi-billions and continue to grow.
Given SPEX’s prior successes, they could be best suited to help advance these key projects to market and provide help to those suffering.
SPEX also released the following info that is sure to grab the attention of the Street
The Company has total assets of $11,937,000.
The Company has liabilities of $982,000.
A snapshot of a data point for sure, but compelling, confidence inspiring statistics that reflect a risk-taker of a company with interests in a myriad of lucrative verticals which cashed in big on one of its earliest investments, dropping two million shares into the proforma when an early stage investment IPO'd and a hypothetical windfall became an actual one.
The asset/liability ratio alone should raise Spherix's street cred above other companies in any of its targeted industries where blue sky optimism and 'someday' dialogue too often suffice in lieu of real asset gains or profits.
But perhaps what is most compelling when considered in the context of this stirring asset/liability chasm is another singular number:
The Company has 2,010,074 shares of common stock outstanding.
Nearly $12 million in assets as of the last Q, just under a million in debt, and roughly 2 million shares in play. Post that snippet on your favorite stock message board and see what the natives say.
We'll let the reader do the math on their own as the share price changes daily, but it's more than a little interesting to consider Spherix's present and future simply going by the numbers.
Source: www.accesswire.com/5...ports-By-the-Numbers
About Spherix
Spherix Incorporated is a technology development company committed to the fostering of innovative ideas. Spherix Incorporated was formed in 1967 as a scientific research company.
Their activities generally include the acquisition and development of technology through internal or external research and development. In addition, they seek to acquire existing rights to intellectual property through the acquisition of already issued patents and pending patent applications, both in the United States and abroad. They may alone, or in conjunction with others, develop products and processes associated with technology development and monetizing related intellectual property.
Company Highlights:
Spherix Reports First Quarter 2019 Results of $11,937,000 in Assets and $982,000 in Liabilities
Company filed its Form-10Q for the period ended March 31, 2019, which showed total assets of $11,937,000.00 and liabilities of $982,000.00, with 2,010,074 shares of common stock outstanding.
In addition, the Company announced a restructuring of the terms of its proposed merger with CBM BioPharma, Inc. (CBM), a Delaware corporation. In lieu of the previously announced merger, the Company announced the terms of an Asset Purchase Agreement with CBM, whereby the Company purchased substantially all of CBM's assets including, among other things, a license agreement, university contracts, and contracts with a Chief Scientific Officer, as well as a Scientific advisory board. The revised agreement is significantly less dilutive to Spherix shareholders, as Spherix is paying $8,000,000.00 to CBM in total compensation, as opposed to the previously announced $16,500,000.00, as more fully set forth in the Company's filings. The acquisition of CBM's assets is pending shareholder approval.
In addition, the Company announced that it purchased a 20% shareholder's stake in CBM along with certain interests in DatChat, Inc. Spherix was successful in acquiring these interests in CBM at a substantial discount to CBM's valuation. The 20% shareholder stake in CBM will give Spherix the ability to participate in any dividends declared by CBM in the future.
Mr. Anthony Hayes, CEO of Spherix stated, "The revised negotiated terms with CBM BioPharma in the Asset Purchase Agreement will introduce valuable assets into the Spherix family. The new agreement will be less dilutive to Spherix shareholders. I am also pleased to note that CBM has received some early, favorable correspondence from the Patent Office about its University of Texas patent applications. We will provide additional information as it comes available, but it is certainly a positive development for CBM."
"Post-closing, Spherix shareholders will still own a majority interest in the Company. Further, Spherix's 20% ownership in CBM is an accretive benefit to Spherix shareholders and by having an ownership interest in CBM, Spherix will participate in any dividend distributions made by CBM in the future. This may include cash dividends that might result from the future sale of Spherix stock. We look forward to sharing additional information with our shareholders about the proposed asset purchase in the upcoming weeks through both investor outreach and our upcoming SEC filings."
Market Outlook:
Pancreatic cancer is set to become the second leading cause of cancer-related deaths in the US in 2020 after lung cancer.
The global pancreatic cancer treatment market size was valued at USD 1.7 billion in 2015. The rising prevalence of obesity, alcohol consumption, and smoking is expected to propel the market growth.
According to the Leukemia & Lymphoma Society, “there are an estimated 399,967 people living with or in remission from leukemia in the US” and “in 2019, 61,780 people are expected to be diagnosed with leukemia.”
The Global Leukemia Therapeutic Market is expected to exceed more than US$ 12.50 Billion by 2024 at a CAGR of 4% in the given forecast period.
There is a huge need for innovation and improvement to address these serious diseases.
Technical Analysis
Like all low-float alerts, SPEX has the potential to run-up big on volume.
The chart looks extremely attractive at the moment.
The price appears to have consolidated, and is now in the apex with an explosive move higher impending.
Its retrace appears complete, and looks to have developed strong support at these levels.
Bases on our very own chart analysis, we see the potential for a move of over +70%!
The Bottom-Line
SPEX looks like a winner in both the financial and technical sides.
This should be the only ticker on your radar tomorrow.
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
Best Regards,
The TopMarketGainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by World Wide Holdings LLC to conduct a one-day investor relations advertising and marketing campaign for SPEX. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.